MX2021007376A - Moléculas bifuncionales para el direccionamiento lisosómico y composiciones y métodos relacionados. - Google Patents
Moléculas bifuncionales para el direccionamiento lisosómico y composiciones y métodos relacionados.Info
- Publication number
- MX2021007376A MX2021007376A MX2021007376A MX2021007376A MX2021007376A MX 2021007376 A MX2021007376 A MX 2021007376A MX 2021007376 A MX2021007376 A MX 2021007376A MX 2021007376 A MX2021007376 A MX 2021007376A MX 2021007376 A MX2021007376 A MX 2021007376A
- Authority
- MX
- Mexico
- Prior art keywords
- bifunctional molecules
- methods
- lysosomal targeting
- molecules
- related compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Abstract
Se proporcionan moléculas bifuncionales que incluyen un primer resto que se une específicamente a una molécula de superficie celular o molécula extracelular, y un segundo resto que se une específicamente a una molécula de direccionamiento lisosómico. Las moléculas bifuncionales encuentran uso, por ejemplo, para la degradación dirigida de moléculas de superficie celular y moléculas extracelulares (por ejemplo, proteínas) a través de la ruta endosoma/lisosoma. También se proporcionan composiciones y kits que incluyen las moléculas bifuncionales, así como también métodos para usar las moléculas bifuncionales. También se proporcionan métodos para fabricar moléculas bifuncionales.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862782193P | 2018-12-19 | 2018-12-19 | |
US201962932347P | 2019-11-07 | 2019-11-07 | |
PCT/US2019/067228 WO2020132100A1 (en) | 2018-12-19 | 2019-12-18 | Bifunctional molecules for lysosomal targeting and related compositions and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021007376A true MX2021007376A (es) | 2021-09-21 |
Family
ID=71102305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021007376A MX2021007376A (es) | 2018-12-19 | 2019-12-18 | Moléculas bifuncionales para el direccionamiento lisosómico y composiciones y métodos relacionados. |
Country Status (12)
Country | Link |
---|---|
US (3) | US20220023434A1 (es) |
EP (1) | EP3897747A4 (es) |
JP (1) | JP2022513299A (es) |
KR (1) | KR20210104828A (es) |
CN (1) | CN113301925A (es) |
AU (1) | AU2019404061A1 (es) |
BR (1) | BR112021012113A2 (es) |
CA (1) | CA3123086A1 (es) |
IL (1) | IL283958A (es) |
MX (1) | MX2021007376A (es) |
SG (1) | SG11202106209RA (es) |
WO (1) | WO2020132100A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220023434A1 (en) | 2018-12-19 | 2022-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional Molecules for Lysosomal Targeting and Related Compositions and Methods |
AU2020364074A1 (en) * | 2019-10-10 | 2022-05-19 | Yale University | Targeted bifunctional degraders |
IL294515A (en) | 2020-01-31 | 2022-09-01 | Avilar Therapeutics Inc | Compounds bind asgpr to degrade extracellular proteins |
MX2022010538A (es) | 2020-02-28 | 2022-09-21 | Genzyme Corp | Polipeptidos de union modificados para conjugacion optimizada con farmacos. |
US20230257468A1 (en) * | 2020-06-30 | 2023-08-17 | The Board Of Trustees Of The Leland Stanford Junior University | CIS-Binding Siglec Agonists and Related Compositions And Methods |
WO2022035997A1 (en) * | 2020-08-11 | 2022-02-17 | Avilar Therapeutics, Inc. | In vivo assembly of asgpr binding therapeutics |
CN114438088A (zh) * | 2020-11-03 | 2022-05-06 | 韩达 | 一种溶酶体靶向的核酸嵌合体的制备及应用 |
WO2022157626A1 (en) * | 2021-01-19 | 2022-07-28 | Novartis Ag | Degradation of extracellular targets |
CN114573714B (zh) * | 2021-03-15 | 2023-03-31 | 北京大学 | 用于靶分子修饰的缀合物及其制备方法 |
EP4314050A1 (en) * | 2021-04-02 | 2024-02-07 | The Board of Trustees of the Leland Stanford Junior University | Bispecific molecules and related compositions and methods |
WO2022235699A2 (en) * | 2021-05-03 | 2022-11-10 | Avilar Therapeutics, Inc. | Potent asgpr-binding compounds for the degradation of immunoglobulins and other proteins |
EP4359430A2 (en) * | 2021-06-23 | 2024-05-01 | Lycia Therapeutics, Inc. | Bifunctional compounds containing igf-2 polypeptides |
AU2022310346A1 (en) | 2021-07-14 | 2024-01-25 | Lycia Therapeutics, Inc. | M6pr cell surface receptor binding compounds and conjugates |
CA3228014A1 (en) | 2021-07-30 | 2023-02-16 | Vib Vzm | Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation |
CN117343197A (zh) * | 2021-10-15 | 2024-01-05 | 中山大学 | 重组融合抗体 |
CN114522244B (zh) * | 2022-01-28 | 2023-09-01 | 浙江大学医学院附属第四医院 | 视黄酸修饰的lytac分子及其制备方法和应用 |
FR3132634A1 (fr) * | 2022-02-15 | 2023-08-18 | Nanomedsyn | Composés bifonctionnels ciblant le récepteur du mannose 6-phosphate cation-indépendant |
WO2023178202A2 (en) * | 2022-03-15 | 2023-09-21 | Yale University | Bifunctional small molecules to target the selective degradation of circulating proteins |
WO2023178179A2 (en) * | 2022-03-15 | 2023-09-21 | Yale University | Bi-functional molecules to degrade circulating proteins |
WO2023183413A2 (en) * | 2022-03-22 | 2023-09-28 | Wisconsin Alumni Research Foundation | Transferrin-based lysosome targeting degraders |
WO2023247754A1 (en) * | 2022-06-23 | 2023-12-28 | Draupnir Bio Aps | Bifunctional molecules that selectively induce degradation of extracellular targets in lysosomes |
WO2024003300A1 (en) * | 2022-06-30 | 2024-01-04 | Aptadegrad, S.L. | Dna aptamer conjugates recognizing and degrading coronavirus proteins |
GB202211100D0 (en) * | 2022-07-29 | 2022-09-14 | Stam Jord Cornelis | Lysosomal degradation |
GB202212077D0 (en) | 2022-08-18 | 2022-10-05 | Tribune Therapeutics Ab | Agents that inhibit ccn ligand-induced signalling for treating disease |
WO2024068753A1 (en) * | 2022-09-28 | 2024-04-04 | Glycoera Ag | Glycan-mediated protein degradation |
WO2024089609A1 (en) | 2022-10-25 | 2024-05-02 | Ablynx N.V. | Glycoengineered fc variant polypeptides with enhanced effector function |
WO2024092033A1 (en) * | 2022-10-26 | 2024-05-02 | Amgen Inc. | Multispecific molecules for clearance of immunoglobulins in the treatment of autoantibody-induced diseases |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993006216A1 (en) | 1991-09-26 | 1993-04-01 | Oklahoma Medical Research Foundation | Fusion proteins targeted to lysosomes, for the treatment of aids |
DK129293D0 (da) | 1993-11-16 | 1993-11-16 | Carlsberg Lab | Carbonhydratholdige forbindelser, der kan binde sig til carbonhydratbindende receptorer |
US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
CA2318981A1 (en) * | 1998-02-09 | 1999-08-12 | Genzyme Corporation | Nucleic acid delivery vehicles |
US6093382A (en) | 1998-05-16 | 2000-07-25 | Bracco Research Usa Inc. | Metal complexes derivatized with folate for use in diagnostic and therapeutic applications |
CA2345932C (en) | 1998-10-08 | 2010-07-13 | Stichting Voor De Technische Wetenschappen | Peptide-based carrier devices for stellate cells |
US6426208B1 (en) | 1999-11-12 | 2002-07-30 | Harbor-Ucla Research And Education Institute | Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof |
US20040009907A1 (en) | 2001-02-26 | 2004-01-15 | Alsobrook John P. | Proteins and nucleic acids encoding same |
WO2001080883A1 (en) * | 2000-04-26 | 2001-11-01 | Elusys Therapeutics, Inc. | Bispecific molecules and uses thereof |
EP1399435A2 (en) | 2000-09-01 | 2004-03-24 | Biogen, Inc. | Pyridine derivatives useful as cd40:cd154 binding interruptors and use thereof to treat immunological complications |
JP4588296B2 (ja) | 2001-04-05 | 2010-11-24 | ジョンズ・ホプキンス・ユニバーシティ | キメラワクチン |
US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
US20030049203A1 (en) | 2001-08-31 | 2003-03-13 | Elmaleh David R. | Targeted nucleic acid constructs and uses related thereto |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
ES2564688T3 (es) * | 2001-10-10 | 2016-03-28 | Ratiopharm Gmbh | Remodelación y glicoconjugación de poli(éter) a eritropoyetina |
US7485314B2 (en) | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
US20050191309A1 (en) | 2002-05-06 | 2005-09-01 | Kakkis Emil D. | Induction of antigen specific immunologic tolerance |
AU2002950217A0 (en) | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
US7648966B2 (en) | 2003-05-20 | 2010-01-19 | Pharmaxis Pty Limited | Mannose-6-phosphonate compounds for the treatment of inflammatory diseases |
US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
US8889127B2 (en) | 2004-07-01 | 2014-11-18 | Icahn School Of Medicine At Mount Sinai | Targeted protein replacement for the treatment of lysosomal storage disorders |
GB0423405D0 (en) | 2004-10-21 | 2004-11-24 | Novartis Ag | Organic compounds |
EP1745802A1 (en) | 2005-07-20 | 2007-01-24 | Kreatech Biotechnology B.V. | Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes |
US20070104648A1 (en) | 2005-11-09 | 2007-05-10 | Glyconix Corporation | Compositions, methods of preparing amino acids, and nuclear magnetic resonance spectroscopy |
EP2009990B1 (en) | 2006-04-07 | 2016-09-21 | The Board of Regents of The University of Texas System | Methods and compositions related to adenoassociated virus-phage particles |
US20080057072A1 (en) | 2006-08-31 | 2008-03-06 | Alcon Manufacturing, Ltd. | Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disorders |
RU2500685C2 (ru) | 2006-11-10 | 2013-12-10 | Кара Терапеутикс, Инк | Синтетические пептидные амиды |
WO2008089339A2 (en) * | 2007-01-18 | 2008-07-24 | Genzyme Corporation | Oligosaccharide conjugates for cellular targeting |
US8546425B2 (en) | 2008-09-17 | 2013-10-01 | Purdue Research Foundation | Folate receptor binding conjugates of antifolates |
JP2012525369A (ja) | 2009-04-28 | 2012-10-22 | ファーマキシス リミテッド | 創傷および線維性障害の治療のためのホスホテトラヒドロピラン化合物 |
CA2766614C (en) | 2009-07-03 | 2018-06-19 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Compounds targeting the cation-independent mannose 6-phosphate receptor |
EP2480235A4 (en) | 2009-09-24 | 2013-05-08 | Univ Louisville Res Found | NEW IODO-PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ILLNESSES AND SUFFERING IN CONNECTION WITH THE MACROPHAGE MIGRATION-INHIBITING FACTOR |
FR2952372B1 (fr) | 2009-11-10 | 2012-03-23 | Centre Nat Rech Scient | Nouveaux derives de mannopyranoside ayant une activite anticancereuse |
EP2343081A1 (en) | 2009-12-31 | 2011-07-13 | Rijksuniversiteit Groningen | Interferon analogs |
US20120121592A1 (en) * | 2010-10-13 | 2012-05-17 | Baylor Research Institute | Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells |
TR201802230T4 (tr) | 2011-05-27 | 2018-03-21 | Amicus Therapeutics Inc | Lizozomal depo hastalıklarının gelişmiş tedavileri için hedefleyici peptitlerin rekombinan lizozomal enzimler üzerine kenetlenmesi için yöntemler. |
EP2825553B1 (en) * | 2012-03-14 | 2018-07-25 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
CA3140358A1 (en) | 2012-07-31 | 2014-02-06 | Bioasis Technologies, Inc. | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
WO2014082080A2 (en) | 2012-11-26 | 2014-05-30 | Callidus Biopharma, Inc. | Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases |
US20140212423A1 (en) | 2012-12-04 | 2014-07-31 | Abbvie, Inc. | Blood-brain barrier penetrating dual specific binding proteins |
EP2981551B1 (en) | 2013-02-20 | 2020-06-03 | Valerion Therapeutics, LLC | Methods and compositions for treatment of pompe disease |
EP2991677B1 (en) | 2013-05-03 | 2020-07-15 | Yale University | Synthetic antibody mimetic compounds (syams) targeting cancer, especially prostate cancer |
TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗-prlr抗體及其用途 |
US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
RS64072B1 (sr) | 2014-03-19 | 2023-04-28 | Genzyme Corp | Mesto-specifični glikoinženjering ciljnih delova |
AU2015262993B2 (en) | 2014-05-19 | 2019-11-07 | Pfizer Inc. | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR |
WO2015191934A2 (en) | 2014-06-11 | 2015-12-17 | Abbvie Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases |
CA2956469A1 (en) | 2014-08-11 | 2016-02-18 | Shire Human Genetic Therapies, Inc. | Mannose-6-phosphate bearing peptides fused to lysosomal enzymes |
WO2016040305A1 (en) | 2014-09-08 | 2016-03-17 | Temple University-Of The Commonwealth System Of Higher Education | Pcsk9 inhibitors and methods of use thereof |
WO2016057769A2 (en) | 2014-10-09 | 2016-04-14 | Genzyme Corporation | Glycoengineered antibody drug conjugates |
US20160166679A1 (en) | 2014-12-12 | 2016-06-16 | Purdue Research Foundation | Method of treatment using folate conjugates and tyrosine kinase inhibitors |
EA038973B1 (ru) * | 2015-07-06 | 2021-11-17 | Ридженерон Фармасьютикалз, Инк. | Полиспецифические антигенсвязывающие молекулы и их применения |
FR3041345B1 (fr) | 2015-09-18 | 2019-06-14 | Nanomedsyn | Composes polysaccharides multi-fonctionnalises et leur utilisation pour cibler le recepteur du mannose 6-phosphate cation-independant |
EP3356415B1 (en) * | 2015-09-29 | 2024-05-01 | Amgen Inc. | Asgr inhibitors for reduzing cholesterol levels |
CN108367056B (zh) | 2015-12-08 | 2022-12-23 | 瑞泽恩制药公司 | 用于内化酶的组合物和方法 |
EP3411406A1 (en) * | 2016-02-05 | 2018-12-12 | Genmab A/S | Multispecific antigen-binding molecule with improved internalization characteristics |
CA3027194A1 (en) | 2016-06-09 | 2017-12-14 | Centre National De La Recherche Scientifique (Cnrs) | Raav with chemically modified capsid |
KR20200015932A (ko) | 2017-06-07 | 2020-02-13 | 리제너론 파마슈티칼스 인코포레이티드 | 효소 내재화를 위한 조성물 및 방법 |
CA3134765A1 (en) | 2018-04-09 | 2019-10-17 | Yale University | Bi-functional molecules to degrade circulating proteins |
EP3773727A4 (en) | 2018-04-09 | 2022-05-04 | Yale University | BIFUNCTIONAL SMALL MOLECULES TO TARGETING THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS |
US20220023434A1 (en) | 2018-12-19 | 2022-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional Molecules for Lysosomal Targeting and Related Compositions and Methods |
CN114729331A (zh) | 2019-07-11 | 2022-07-08 | 法国国家科学研究中心 | 化学修饰的腺相关病毒 |
AU2020364074A1 (en) | 2019-10-10 | 2022-05-19 | Yale University | Targeted bifunctional degraders |
BR112022006781A2 (pt) | 2019-10-10 | 2022-06-28 | Univ Yale | Anticorpos modificados como degradadores moleculares através de receptores celulares |
-
2019
- 2019-12-18 US US17/311,779 patent/US20220023434A1/en not_active Abandoned
- 2019-12-18 EP EP19901042.2A patent/EP3897747A4/en active Pending
- 2019-12-18 BR BR112021012113-7A patent/BR112021012113A2/pt unknown
- 2019-12-18 MX MX2021007376A patent/MX2021007376A/es unknown
- 2019-12-18 KR KR1020217022461A patent/KR20210104828A/ko unknown
- 2019-12-18 JP JP2021534939A patent/JP2022513299A/ja active Pending
- 2019-12-18 SG SG11202106209RA patent/SG11202106209RA/en unknown
- 2019-12-18 CN CN201980087886.9A patent/CN113301925A/zh active Pending
- 2019-12-18 AU AU2019404061A patent/AU2019404061A1/en active Pending
- 2019-12-18 CA CA3123086A patent/CA3123086A1/en active Pending
- 2019-12-18 WO PCT/US2019/067228 patent/WO2020132100A1/en unknown
-
2021
- 2021-06-14 IL IL283958A patent/IL283958A/en unknown
- 2021-10-12 US US17/499,272 patent/US11787865B2/en active Active
-
2023
- 2023-09-08 US US18/244,121 patent/US20230416377A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2019404061A1 (en) | 2021-07-22 |
JP2022513299A (ja) | 2022-02-07 |
WO2020132100A1 (en) | 2020-06-25 |
EP3897747A1 (en) | 2021-10-27 |
IL283958A (en) | 2021-07-29 |
US20220025057A1 (en) | 2022-01-27 |
US20220023434A1 (en) | 2022-01-27 |
US20230416377A1 (en) | 2023-12-28 |
US11787865B2 (en) | 2023-10-17 |
CN113301925A (zh) | 2021-08-24 |
SG11202106209RA (en) | 2021-07-29 |
CA3123086A1 (en) | 2020-06-25 |
BR112021012113A2 (pt) | 2021-09-08 |
KR20210104828A (ko) | 2021-08-25 |
EP3897747A4 (en) | 2022-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021007376A (es) | Moléculas bifuncionales para el direccionamiento lisosómico y composiciones y métodos relacionados. | |
EP4218802A3 (en) | Conjugates for targeted cell surface editing | |
EA202091486A1 (ru) | Способы и композиции для поляризации макрофагов | |
CY1119183T1 (el) | Πεπτιδια λυσοσωμiκης στοχευσης και χρησεις αυτων | |
WO2018226732A8 (en) | MULTIBIOTIC AGENTS AND METHODS OF USE THEREOF | |
MX2022010515A (es) | Conjugacion mediada por transglutaminasa. | |
PH12019502333A1 (en) | Targeted compositions | |
ME01009B (me) | Kristalni oblici dimetoksi docetaksela i postupak za njihovo dobijanje | |
MX2021005130A (es) | Metodos terapeuticos. | |
WO2015151080A3 (en) | Specific conjugation of cell-binding molecules | |
MD3645553T2 (ro) | Particule virale recombinate modificate cu tropism și utilizările acestora pentru introducerea țintită a materialului genetic în celulele umane | |
BR112013003825A2 (pt) | conjugados, partículas, composições e métodos relacionados | |
EP3838298A3 (en) | Psma binding ligand-linker conjugates and methods for using | |
BRPI0810332A2 (pt) | "politioéter envolvido com amina/hidroxi" | |
BR112018016450A2 (pt) | composições intensificadoras de vcn e métodos de uso das mesmas | |
MX2017008215A (es) | Conjugados de farmacos proteinas de union que comprenden derivados de antraciclina. | |
MX2022001776A (es) | Terapias de combinacion de inmuno oncologia con conjugados de il-2. | |
MX2017013154A (es) | Conjugados anticuerpo-farmaco de sitio especifico. | |
GB0718957D0 (en) | Optical imaging agents | |
BR112016016202A2 (pt) | Construtos de direcionamento de receptores e uso dos mesmos | |
MX2021011584A (es) | Anticuerpos que penetran en celulas. | |
WO2019147309A3 (en) | Rna nanostructures and methods of making and using rna nanostructures | |
MX2023007032A (es) | Moléculas bifuncionales novedosas para la degradación de proteínas dirigidas. | |
MX2009010288A (es) | Dispositivo para la administracion de composiciones viscosas. | |
CO2021014748A2 (es) | Conjugado de anticuerpo anti-bcma, composiciones que lo comprenden, y métodos de fabricación y uso del mismo |